SCHEMBL18943090

SCHEMBL18943090

O=C(O)CCCCCCN1CCC(F)(F)C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 4/20 0.42
▸ PTGS2 P35354 4/20 0.42
▸ PTGER4 P35408 4/20 0.40
▸ PTGER3 P43115 2/20 0.40
▸ PTGER2 P43116 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ PMP22 Q01453 1/20 0.38
▸ ITGB3 P05106 1/20 0.37
▸ ITGA2B P08514 1/20 0.37
▸ TBXAS1 P24557 3/20 0.36
▸ BACE1 P56817 1/20 0.36
▸ BACE2 Q9Y5Z0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19513822 0.69 TSHR (0.47) PTGS1PTGS2MEN1GAAKMT2A
SCHEMBL19513862 0.69 TSHR (0.47) PTGS1PTGS2MEN1GAAKMT2A
SCHEMBL9151143 0.69 TSHR (0.47) PTGS1PTGS2MEN1GAAKMT2A
SCHEMBL7416853 0.69 TSHR (0.47) PTGS1PTGS2MEN1GAAKMT2A
SCHEMBL27763458 0.68 NAAA (0.46) PTGS1PTGS2KDM4EALDH1A1HPGD
SCHEMBL2944990 0.67 TSHR (0.49) PTGS1PTGS2MEN1KMT2ATSHR
SCHEMBL8381328 0.66 CYP1A2 (0.65) PTGS1PTGS2ALDH1A1MEN1KMT2A
SCHEMBL25465029 0.64 PTGS1 (0.57) PTGS1PTGS2ALDH1A1MEN1GAA
SCHEMBL5697933 0.64 PTGS1 (0.61) PTGS1PTGS2ALDH1A1HPGDMEN1
SCHEMBL27248010 0.64 PTGS1 (0.61) PTGS1PTGS2ALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3176162-A1 DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS Cayman Chemical Company, Incorporated (US) 2017-06-07 — — EP disclosed
EP-3175852-A1 DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS Cayman Chemical Company, Incorporated (US) 2017-06-07 — — EP disclosed
Send feedback